EP1617824A1 - Pharmaceutical composition containing ribavirin as active substance and method of manufacturing thereof - Google Patents

Pharmaceutical composition containing ribavirin as active substance and method of manufacturing thereof

Info

Publication number
EP1617824A1
EP1617824A1 EP04729818A EP04729818A EP1617824A1 EP 1617824 A1 EP1617824 A1 EP 1617824A1 EP 04729818 A EP04729818 A EP 04729818A EP 04729818 A EP04729818 A EP 04729818A EP 1617824 A1 EP1617824 A1 EP 1617824A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
mixture
ribavirin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04729818A
Other languages
German (de)
French (fr)
Inventor
Ales Franc
Borek Zaludek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Lachema AS
Original Assignee
Pliva Lachema AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Lachema AS filed Critical Pliva Lachema AS
Publication of EP1617824A1 publication Critical patent/EP1617824A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • This invention relates to a pharmaceutical composition containing ribavirin as active substance and ensuring the perfect stability of the composition, even in case of high ratio of the active substance in it, and the immediate release of the active substance from a dosage form, when administered orally in the form of capsules or tablets.
  • This invention also relates to a method of manufacturing of this pharmaceutical composition.
  • Ribavirin its chemical name being l-beta-D-ribofuranosyl-l,2,4-triazole-3-carboxamide, is a substance having antiviral effects. It is a nucleoside analogue of formula I demonstrating, both in vitro and in vivo, an activity against certain DNA and RNA viruses.
  • the dosage forms of the antiviral agent - ribavirin - used simultaneously with ⁇ 2b interferon or ⁇ 2b peg- interferon are used particularly for combined treatment of chronic hepatitis C.
  • Ribavirin dosage forms having the form of topic preparations (gel, cream), parenteral preparations (hquid injections), oral solid and liquid dosage forms, and dosage forms intended for inhaling, have been described in literature.
  • Ribavirin filled into capsules or tablets represents the dosage form particularly suitable for oral application.
  • Virazole TM capsules and Rebetol ® capsules manufactured by the companies ICN and Schering-Plough, respectively, are particularly used in the current clinical practice.
  • Ribavirin - the medicinal substance, both unprocessed and processed by milling and/or sieving to obtain the particle size suitable for pharmaceutical use - has a low tap density and a bad bulk density; this makes the preparation of the dosage form, particularly mixing of the active substance with suitable pharmaceutically acceptable excipients, and also particularly reproducible and sufficiently quick release of the active substance from the dosage form after being administered to the patient, rather complicated. Due to unsuitable physical characteristics of ribavirin, the capsule filled with Virazole preparation contains a badly flowing powder having a low and fluctuating tap density ranging between 0.320 and 0.449 g.cm "3 . Such fluctuation frequently results in a significant variability of capsule weights during filling, particularly when high-duty encapsulation machines are used.
  • Virazole TM capsules have other deficiencies, namely, an unsuitable disintegration time of the said dosage form and an unsuitable release rate of the active substance during the dissolution test.
  • the deficiencies mentioned above are partially solved in Rebetol ® preparation, the capsules of which, containing a high portion of the active component in the composition, are prepared using the dry granulation method according to WO 9932128.
  • the substance of the solution of the problem consists in homogenization of an effective ribavirin quantity with an effective quantity of a pharmaceutically acceptable releasing agent and with at least one pharmaceutically acceptable filler.
  • the homogeneous mixture is compacted using a compression force ranging between 50 and 75 kN for the time sufficient for manufacturing of appropriate compacts (aggregates).
  • a granulate prepared using further milling of compacted agglomerates usually consists of fragments having uneven forms and sharp edges which affect adversely the liquidity of the composition, h addition, the granulate usually contains also a portion of superfine particles, the quantity of which depends on the agglomerate rigidity that affects significantly its bulk characteristics.
  • the granulates manufactured using the dry granulation method also have a decreased porosity due to their compacting.
  • the above mentioned facts result in a longer release time of the active substance from the composition like this.
  • the cohesive properties advantageous for further possible processing into tablets are gradually lost during the processing of the granulate using the dry granulation method when compacting is also performed.
  • the tablets have in this case a reduced cohesion (i.e. low radial strength) and a high abrasion.
  • the invention relates to a pharmaceutical composition containing ribavirin as active substance in the mixture with at least one pharmaceutically acceptable excipient characterized in that it is a freely flowing granulate prepared using the wet granulation of a mixture, wetted with water, of ribavirin and at least one pharmaceutically acceptable filler selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals, and optionally at least one pharmaceutically acceptable excipient.
  • the mixture wetted with water and intended for the wet granulation contains advantageously ribavirin at the amount equal to at least 65 % by weight, and at least one pharmaceutically acceptable filler insoluble in water, at the amount equal to not more than 25 % by weight, related always to the dry-weight basis of the mixture mentioned.
  • the composition contains advantageously microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate or hydrated forms thereof as the pharmaceutically acceptable fillers insoluble in water.
  • the mixture advantageously contains at least one pharmaceutically acceptable binder and/or releasing agent.
  • Polysaccharides and/or modified polysaccharides can be, for example, used as the releasing agent.
  • the pharmaceutical composition according to the invention forms the granulate which is filled into capsules, particularly gelatine capsules, or into sacks.
  • the granulate obtained can be also compacted into tablets.
  • the pharmaceutical composition according to the invention forms the granulate having a predominantly regular and rounded shape and having the good liquidity.
  • a pharmaceutically acceptable slipping agent for example, magnesium stearate, is advantageously added.
  • a pharmaceutically acceptable external release agent for example, polysaccharide and/or modified polysaccharide, is added.
  • the invention relates also to the method of manufacturing of the pharmaceutical composition according to the invention characterized in that the mixture of ribavirin wetted with water, at least one pharmaceutically acceptable filler insoluble in water selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals, and at least one pharmaceutically acceptable excipient is granulated under wet conditions to obtain the granulate, then optionally at least one pharmaceutically acceptable external releasing agent and/or at least one pharmaceutically acceptable slipping agent are added to the granulate obtained, and the granulate, or optionally the mixture, obtained are optionally filled into capsules or sacks or compacted into tablets.
  • the manufacturing method described is simple and has no special demands for the processing equipment.
  • the granulate obtained has a high portion of the active substance - ribavirin - and a predominantly rounded shape and its particle size ensures the good liquidity of the composition.
  • the composition according to the invention has also a very good disintegration and a good release of the active substance during the dissolution tests.
  • the wet granulation method consists in that the liquid phase is added to the dry mixture while being simultaneously agitated in a suitable equipment.
  • the wet granulate prepared using the process mentioned is optionally extruded, dried and then processed into the finished form.
  • the mixture processed using the wet granulation has a significantly better aggregation and thus particularly drugs with high portions of the active substance in the composition obtain during the wet granulation the necessary bulk characteristics that represent one of the necessary conditions for their further processing into the final dosage forms because the formation of fragments of undefined shapes with sharp edges and a portion of superfine particles affecting adversely their uniform filling into capsules or matrixes of a tablet-making machine is thus eliminated.
  • the granulates prepared using the wet granulation retain also their natural porosity, enhancing their plastic defor ability, enabling also their good compacting into tablets.
  • fillers insoluble in water selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals should be used in preparation of ribarivin dosage form in the wet granulation that in combination with a hydrophilic active substance ensures advantageously the instant release of the active substance at the amount equal to not more than 25 % by weight, related to the dry-weight basis of the mixture intended for the granulation.
  • a hydrophilic active substance ensures advantageously the instant release of the active substance at the amount equal to not more than 25 % by weight, related to the dry-weight basis of the mixture intended for the granulation.
  • at least 80 % by weight of the active substance were released within 30 minutes because the fillers mentioned above are not dissolved during the wet granulation and therefore no interactions with hydrophilic active substance occurs.
  • a porous granulate By such unique combination of the hydrophilic active substance and the insoluble filler, a porous granulate, the porosity of which enables a quick penetration of the dissolution medium into the dosage form and thus the activation of the release agent, is formed during the process of the preparation.
  • hydrophilic fillers as lactose
  • the fillers insoluble in water also prevent an excessive wetting of the granulate and thus enable maintaining the standard production even during possible changes of the physical parameters of the active substance.
  • the granulate amount in the individual dosage form is 300 mg.
  • the granulate amount in the individual dosage form, a tablet or a capsule is 300 mg.
  • the granulate amount in the individual dosage form, a tablet or a capsule is 300 mg.
  • Amount of the active substance released is given in % by weight
  • Amount of the active substance released is given in % by weight
  • This dissolution profile is represented graphically in Fig. 2.

Abstract

The invention relates to a pharmaceutical composition which is a freely flowing granulate prepared using the wet granulation of a mixture, wetted with water, of ribavirin, at least one pharmaceutically acceptable filler selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals, and optionally at least one pharmaceutically acceptable excipient, and also a method of the manufacture thereof. The pharmaceutical composition according to the invention ensures the perfect stability of the composition, even in case of a high ratio of the active substance in it, and the immediately release of the active substance from a dosage form, when administered orally in the form of capsules or tablets.

Description

Pharmaceutical Composition Containing Ribavirin as Active Substance and Method of Manufacturing Thereof
Field of the Invention
This invention relates to a pharmaceutical composition containing ribavirin as active substance and ensuring the perfect stability of the composition, even in case of high ratio of the active substance in it, and the immediate release of the active substance from a dosage form, when administered orally in the form of capsules or tablets. This invention also relates to a method of manufacturing of this pharmaceutical composition.
Background of the Invention
Ribavirin, its chemical name being l-beta-D-ribofuranosyl-l,2,4-triazole-3-carboxamide, is a substance having antiviral effects. It is a nucleoside analogue of formula I demonstrating, both in vitro and in vivo, an activity against certain DNA and RNA viruses. The dosage forms of the antiviral agent - ribavirin - used simultaneously with α2b interferon or α2b peg- interferon are used particularly for combined treatment of chronic hepatitis C.
Various ribavirin dosage forms, having the form of topic preparations (gel, cream), parenteral preparations (hquid injections), oral solid and liquid dosage forms, and dosage forms intended for inhaling, have been described in literature. Ribavirin filled into capsules or tablets represents the dosage form particularly suitable for oral application. Virazole™ capsules and Rebetol® capsules manufactured by the companies ICN and Schering-Plough, respectively, are particularly used in the current clinical practice.
Ribavirin - the medicinal substance, both unprocessed and processed by milling and/or sieving to obtain the particle size suitable for pharmaceutical use - has a low tap density and a bad bulk density; this makes the preparation of the dosage form, particularly mixing of the active substance with suitable pharmaceutically acceptable excipients, and also particularly reproducible and sufficiently quick release of the active substance from the dosage form after being administered to the patient, rather complicated. Due to unsuitable physical characteristics of ribavirin, the capsule filled with Virazole preparation contains a badly flowing powder having a low and fluctuating tap density ranging between 0.320 and 0.449 g.cm"3. Such fluctuation frequently results in a significant variability of capsule weights during filling, particularly when high-duty encapsulation machines are used. In addition, Virazole™ capsules have other deficiencies, namely, an unsuitable disintegration time of the said dosage form and an unsuitable release rate of the active substance during the dissolution test. The deficiencies mentioned above are partially solved in Rebetol® preparation, the capsules of which, containing a high portion of the active component in the composition, are prepared using the dry granulation method according to WO 9932128. The substance of the solution of the problem consists in homogenization of an effective ribavirin quantity with an effective quantity of a pharmaceutically acceptable releasing agent and with at least one pharmaceutically acceptable filler. The homogeneous mixture is compacted using a compression force ranging between 50 and 75 kN for the time sufficient for manufacturing of appropriate compacts (aggregates). These compacts are then crushed by milling of sieving and then mixed with a slipping substance and filled into capsules. This method enables obtaining ribavirin composition having high contents of the active substance, having a high tap density at least 0.6 g.cm"3 and a good dissolution profile. The disadvantage of the said problem solution using dry granulation is a rather complex manufacturing demanding a special processing equipment. Further factors limiting the dry granulation method seem to be the must to ensure a high plastic deformability of the powder mixture and also a heat stress of the mixture mentioned when higher compacting pressures necessary for formation of sufficiently rigid agglomerates are used. A granulate prepared using further milling of compacted agglomerates usually consists of fragments having uneven forms and sharp edges which affect adversely the liquidity of the composition, h addition, the granulate usually contains also a portion of superfine particles, the quantity of which depends on the agglomerate rigidity that affects significantly its bulk characteristics. The granulates manufactured using the dry granulation method also have a decreased porosity due to their compacting. The above mentioned facts result in a longer release time of the active substance from the composition like this. The cohesive properties advantageous for further possible processing into tablets are gradually lost during the processing of the granulate using the dry granulation method when compacting is also performed. The tablets have in this case a reduced cohesion (i.e. low radial strength) and a high abrasion.
These problems are essentially solved by the pharmaceutical composition and the method of manufacturing thereof according to the invention.
Summary of the Invention
The invention relates to a pharmaceutical composition containing ribavirin as active substance in the mixture with at least one pharmaceutically acceptable excipient characterized in that it is a freely flowing granulate prepared using the wet granulation of a mixture, wetted with water, of ribavirin and at least one pharmaceutically acceptable filler selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals, and optionally at least one pharmaceutically acceptable excipient.
The mixture wetted with water and intended for the wet granulation contains advantageously ribavirin at the amount equal to at least 65 % by weight, and at least one pharmaceutically acceptable filler insoluble in water, at the amount equal to not more than 25 % by weight, related always to the dry-weight basis of the mixture mentioned.
The composition contains advantageously microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate or hydrated forms thereof as the pharmaceutically acceptable fillers insoluble in water. In order to ease granulate formation, its disintegration and ribavirin dissolution from the composition according to the invention, the mixture advantageously contains at least one pharmaceutically acceptable binder and/or releasing agent. Polysaccharides and/or modified polysaccharides can be, for example, used as the releasing agent.
The pharmaceutical composition according to the invention forms the granulate which is filled into capsules, particularly gelatine capsules, or into sacks. The granulate obtained can be also compacted into tablets. The pharmaceutical composition according to the invention forms the granulate having a predominantly regular and rounded shape and having the good liquidity. In order to enhance the liquidity of the granulate mentioned, a pharmaceutically acceptable slipping agent, for example, magnesium stearate, is advantageously added. In order to ensure a good disintegration of the possibly formed agglomerates, a pharmaceutically acceptable external release agent, for example, polysaccharide and/or modified polysaccharide, is added. The invention relates also to the method of manufacturing of the pharmaceutical composition according to the invention characterized in that the mixture of ribavirin wetted with water, at least one pharmaceutically acceptable filler insoluble in water selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals, and at least one pharmaceutically acceptable excipient is granulated under wet conditions to obtain the granulate, then optionally at least one pharmaceutically acceptable external releasing agent and/or at least one pharmaceutically acceptable slipping agent are added to the granulate obtained, and the granulate, or optionally the mixture, obtained are optionally filled into capsules or sacks or compacted into tablets. The manufacturing method described is simple and has no special demands for the processing equipment. The granulate obtained has a high portion of the active substance - ribavirin - and a predominantly rounded shape and its particle size ensures the good liquidity of the composition. The composition according to the invention has also a very good disintegration and a good release of the active substance during the dissolution tests.
The wet granulation method consists in that the liquid phase is added to the dry mixture while being simultaneously agitated in a suitable equipment. The wet granulate prepared using the process mentioned is optionally extruded, dried and then processed into the finished form. The mixture processed using the wet granulation has a significantly better aggregation and thus particularly drugs with high portions of the active substance in the composition obtain during the wet granulation the necessary bulk characteristics that represent one of the necessary conditions for their further processing into the final dosage forms because the formation of fragments of undefined shapes with sharp edges and a portion of superfine particles affecting adversely their uniform filling into capsules or matrixes of a tablet-making machine is thus eliminated. The granulates prepared using the wet granulation retain also their natural porosity, enhancing their plastic defor ability, enabling also their good compacting into tablets.
In order to reach the parameters demanded in the wet granulation, pharmaceutically acceptable fillers insoluble in water selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals should be used in preparation of ribarivin dosage form in the wet granulation that in combination with a hydrophilic active substance ensures advantageously the instant release of the active substance at the amount equal to not more than 25 % by weight, related to the dry-weight basis of the mixture intended for the granulation. In the dissolution tests according to USP, at least 80 % by weight of the active substance were released within 30 minutes because the fillers mentioned above are not dissolved during the wet granulation and therefore no interactions with hydrophilic active substance occurs. By such unique combination of the hydrophilic active substance and the insoluble filler, a porous granulate, the porosity of which enables a quick penetration of the dissolution medium into the dosage form and thus the activation of the release agent, is formed during the process of the preparation. This results in a surprisingly quick granule disintegration, and thus in an enlargement of the active agent surface and thus in its quicker dissolution in the dissolution medium or in gastric juices. It was additionally found out that when hydrophilic fillers, as lactose, are used, the event mentioned above does not occur and disintegration, or dissolution, of the composition is significantly slower.
The fillers insoluble in water also prevent an excessive wetting of the granulate and thus enable maintaining the standard production even during possible changes of the physical parameters of the active substance.
Examples
The examples given below explain in more details the composition and the method of manufacturing of the pharmaceutical composition containing ribavirin as active substance according to the invention, without limiting its scope. Reaching the surprisingly advantageous characteristics of the dosage forms, when the fillers insoluble in water are used in the composition (Examples 1 and 2) in opposition to Example 3 in which lactose was used as the filler soluble in water, is particularly demonstrated.
The weights specified in examples are given in parts by weight.
Example 1
Sieve Ribavirin (1), Avicel (2) and Starch 1500 (3) through a sieve fitted with 0.8 x 0.8 mm mesh in size, mix the mixture in a high-speed masticator for 1 minute;
Add 100 parts by weight of water and mix in the high-speed masticator for 2 minutes;
Press the wet mass through the sieve fitted with 2 x 2 mm mesh in size;
Dry the granulate in a fluidization drier at the temperature of 50 °C until the humidity of 1 - 3 % by weight is reached; homogenize the dry granulate using the sieve fitted with l x l mm mesh in size;
Add Ac-Di-Sol (4) and magnesium stearate (5), and mix in the high-speed masticator for 1 minute;
Fill the granulate into hard gelatine capsules or compact it into tablets having 10 mm in diameter and the radial strength of 70 - 120 N.
The granulate amount in the individual dosage form is 300 mg.
Characteristics of Granulate
Example 2
Sieve Ribavirin (1), DI-CAFOS (2) a Starch 1500 (3) through a sieve fitted with 0.8 x 0.8 mm mesh in size;
Mix the mixture in a high-speed masticator for 1 minute;
Add 80 parts by weight of water and mix in the high-speed masticator for 2 minutes;
Press the wet mass through the sieve fitted with 2 x 2 mm mesh in size;
Dry the granulate in a fluidization drier at the temperature of 50 °C until the humidity of 1 - 3 % by weight is reached;
Homogenize the dry granulate using the sieve fitted with l x l mm mesh in size;
Add Ac-Di-Sol (4) and magnesium stearate (5) and mix in the high-speed masticator for 1 minute;
Fill the granulate into hard gelatine capsules or compact it into tablets having 10 mm in diameter and the radial strength of 70 - 120 N.
The granulate amount in the individual dosage form, a tablet or a capsule is 300 mg.
Characteristics of Granulate
Example 3
Sieve Ribavirin (1), lactose (2) and Starch (3) through a sieve fitted with 0.8 x 0.8 mm mesh in size;
Mix the mixture in a high-speed masticator for 1 minute;
Add 100 parts by weight of water and mix in the high-speed masticator for 2 minutes;
Press the wet mass through the sieve fitted with 2 x 2 mm mesh in size;
Dry the granulate in a fluidization drier at the temperature of 50 °C until the humidity of 1 - 3 % by weight is reached;
Homogenize the dry granulate using the sieve fitted with l x l mm mesh in size;
Add Ac-Di-Sol (4) and magnesium stearate (5) and mix in the high-speed masticator for 1 minute;
Fill the granulate into hard gelatine capsules or compact it into tablets having 10 mm in diameter and the radial strength of 70 - 120 N.
The granulate amount in the individual dosage form, a tablet or a capsule is 300 mg.
Characteristics of Granulate
The advantageous release of the active substance - ribavirin - from capsules or tablets prepared according to the invention is documented in Tables 1 a 2 and Figures 1 a 2 below.
Table 1:
The time course of the active substance - ribavirin - release from hard gelatme capsules prepared according to Examples 1 to 3 in comparison with the preparation Rebetol® (manufactured by Schering-Plough)
Conditions of the dissolution test: According to USP, the basket method
Medium: Water, 900 ml
Speed: 100 rpm
Medium temperature: 37 °C
Amount of the active substance released is given in % by weight
This dissolution profile is represented graphically in Fig. 1. Table 2:
The time course of the active substance - ribavirin - release from tablets prepared according to Examples 1 to 3
Conditions of the dissolution test: According to USP, the basket method
Medium: Water, 900 ml
Speed: 100 rpm
Medium temperature: 37 °C
Amount of the active substance released is given in % by weight
This dissolution profile is represented graphically in Fig. 2.

Claims

PATENT CLAIMS
1. A pharmaceutical composition containing ribavirin as active substance in" the mixture with at least one pharmaceutically acceptable excipient characterized in that it is a freely flowing granulate prepared using the wet granulation of a mixture, wetted with water, of ribavirin, at least one pharmaceutically acceptable filler selected from the group including cellulose and its derivatives, and carbonates, phosphates, sulfates and silicates of metals, and optionally at least one pharmaceutically acceptable excipient.
2. The pharmaceutical composition according to claim 1 characteriz ed in that the mixture wetted with water and intended for the wet granulation contains ribavirin at the amount equal to at least 65 % by weight, and at least one pharmaceutically acceptable filler insoluble in water at the amount equal to not more than 25 % by weight, related always to the dry-weight basis of the mixture mentioned.
3. The pharmaceutical composition according to claim 2 characterized in that the cellulose is microcrystallme cellulose and the phosphate of a metal is selected from the group including calcium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate and hydrated forms thereof.
4. The pharmaceutical composition according to claims l to 3 characterized in th at a binder and/or a release agent is the pharmaceutically acceptable excipient.
5. The pharmaceutical composition according to one of claims 1 to 4 characteriz ed in t h at it is contained in a capsule, particularly a gelatine capsule, or in a sack.
6. The pharmaceutical composition according to one of claims 1 to 4 characteriz ed in t h a t it is compressed in a tablet.
7. The pharmaceutical composition according to one of claims 5 or 6 characteriz ed in that it contains at least one pharmaceutically acceptable external release agent and/or at least one pharmaceutically acceptable slipping agent. A method of manufacturing of the pharmaceutical composition according to one of Claims l to 7 characteriz ed in that a mixture, wetted with water, of ribavirin, at least one pharmaceutically acceptable filler insoluble in water selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals, and at least one pharmaceutically acceptable excipient is granulated under wet conditions to obtain a granulate, then optionally at least one pharmaceutically acceptable external releasing agent and/or at least one pharmaceutically acceptable slipping agent are added to the granulate obtained, and the granulate, or optionally the mixture, obtained are optionally filled into capsules or sacks or compacted into tablets.
EP04729818A 2003-04-29 2004-04-28 Pharmaceutical composition containing ribavirin as active substance and method of manufacturing thereof Withdrawn EP1617824A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20031202A CZ298224B6 (en) 2003-04-29 2003-04-29 Pharmaceutical composition containing ribavirin as active substance and process for its preparation
PCT/CZ2004/000023 WO2004096187A1 (en) 2003-04-29 2004-04-28 Pharmaceutical composition containing ribavirin as active substance and method of manufacturing thereof

Publications (1)

Publication Number Publication Date
EP1617824A1 true EP1617824A1 (en) 2006-01-25

Family

ID=33315391

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04729818A Withdrawn EP1617824A1 (en) 2003-04-29 2004-04-28 Pharmaceutical composition containing ribavirin as active substance and method of manufacturing thereof

Country Status (3)

Country Link
EP (1) EP1617824A1 (en)
CZ (1) CZ298224B6 (en)
WO (1) WO2004096187A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295037A1 (en) 2009-09-11 2011-03-16 Ratiopharm GmbH Pharmaceutical formulation containing Ribavirin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ289081B6 (en) * 1994-09-22 2001-10-17 Akzo Nobel N. V. Process for preparing pharmaceutical medicamentous form and tablet
WO1997016173A1 (en) * 1995-11-02 1997-05-09 Merck Frosst Canada Inc. New technology for wet granulation
ATE295184T1 (en) * 1998-06-05 2005-05-15 Warner Lambert Co STABILIZATION OF COMPOSITIONS CONTAINING ACE INHIBITORS BY MAGNESIUM OXIDE
AU2001239838A1 (en) * 2000-02-24 2001-09-03 Advancis Pharmaceutical Corporation Therapeutic product, use and formulation thereof
US7125565B2 (en) * 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
WO2003039517A1 (en) * 2001-11-02 2003-05-15 Sandoz Inc. Process for preparing quick dissolving, high loading ribavirin compositions
US20040258751A1 (en) * 2002-09-19 2004-12-23 Kerrish Donald J. Composition containing ribavirin and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004096187A1 *

Also Published As

Publication number Publication date
WO2004096187A1 (en) 2004-11-11
CZ298224B6 (en) 2007-07-25
CZ20031202A3 (en) 2005-01-12

Similar Documents

Publication Publication Date Title
Ngwuluka et al. Formulation and evaluation of paracetamol tablets manufactured using the dried fruit of Phoenix dactylifera Linn as an excipient
CN103491949B (en) Tablet-type composition for oral administration and method for producing same
Chatlapalli et al. Physical characterization of HPMC and HEC and investigation of their use as pelletization aids
CA2527686C (en) Cellulose powder
JP5612462B2 (en) Particulate material for dosage forms
EP1847257B1 (en) Solid preparation comprising enteric solid dispersion
EP1847260B1 (en) Solid dispersion preparation
Tobyn et al. Prediction of physical properties of a novel polysaccharide controlled release system. I
CN106659691A (en) Directly compressible composition containing micro-crystalline cellulose
CN1283117A (en) Orally administrable solid ribavirin dosafe forms and process for making them
JP2019142927A (en) Pharmaceutical dosage forms
WO2008111871A1 (en) Peroral memantine-based medicinal preparation and a method for the production thereof
WO1997033571A1 (en) Rapid-release microdispersible ecadotril preparation
JP4812211B2 (en) Low dose tablets and methods of preparation
EP1617824A1 (en) Pharmaceutical composition containing ribavirin as active substance and method of manufacturing thereof
WO1999058114A1 (en) Sustained release tablets, additive compositions therefor and process for producing the same
JP3967767B1 (en) Method for producing intraoral rapidly disintegrating tablet
CN108785273B (en) Entecavir capsule pharmaceutical composition and preparation method thereof
CN112022827B (en) Cyproheptadine hydrochloride quick-release pharmaceutical preparation and preparation method thereof
Tiwari et al. Formulation and In-Vitro Evaluation of Oxcarbazepine Liquisolid Compacts
Balogun-Agbaje et al. Preparation and evaluation of naproxen ternary solid dispersion using genetically modified cassava starch and hydroxypropyl methyl cellulose
EP2826464A1 (en) Sustained release solid dosage preparations
Kalaiselvan et al. A SYSTEMATIC APPROACH TO SCALEMUP THE HIGH-SHEAR GRANULATION PROCESS FOR MEBENDAZOLE TABLETS TO ACHIEVE A SCALE-INDEPENDENT DRUG RELEASE
KR20100052253A (en) Method for preparing solid oral formulation comprising valsartan
WO2008143887A1 (en) Multi-functional particulate delivery system for pharmacologically active ingredients

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20051122

17Q First examination report despatched

Effective date: 20070523

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

18D Application deemed to be withdrawn

Effective date: 20101210

19U Interruption of proceedings before grant

Effective date: 20100101

D18D Application deemed to be withdrawn (deleted)
19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20150413

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PLIVA LACHEMA A.S, V. LIKVIDACI.

INTC Intention to grant announced (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151014